Sickle Cell Disease (SCD) is a painful, lifelong hemoglobinopathy inherited as a missense point mutation in the hemoglobin (Hb) beta-globin gene. This disease has significant impact on quality of life and mortality, thus a substantial medical need exists to reduce the vaso-occlusive crises which underlie the pathophysiology of the disease. The concept that a gaseous molecule may exert biological function has been well known for over one hundred years. Carbon monoxide (CO), although studied in SCD for over 50 years, has recently emerged as a powerful cytoprotective biological response modifier capable of regulating a host of physiologic and therapeutic processes that, at low concentrations, exerts key physiological functions in various models of tissue inflammation and injury. CO is physiologically generated by the metabolism of heme by the heme oxygenase enzymes and is measurable in blood. A substantial amount of preclinical and clinical data with CO have been generated, which provide compelling support for CO as a potential therapeutic in a number of pathological conditions. Data underlying the therapeutic mechanisms of CO, including in SCD, have been generated by a plethora of in vitro and preclinical studies including multiple SCD mouse models. These data show CO to have key signaling impacts on a host of metallo-enzymes as well as key modulating genes that in sum, result in significant anti-inflammatory, anti-oxidant and anti-apoptotic effects as well as vasodilation and anti-adhesion of cells to the endothelium resulting in preservation of vascular flow. CO may also have a role as an antipolymerization HbS agent. In addition, considerable scientific data in the non-SCD literature provide evidence for a beneficial impact of CO on cerebrovascular complications, suggesting that in SCD, CO could potentially limit these highly problematic neurologic outcomes. Research is needed and hopefully forthcoming, to carefully elucidate the safety and benefits of this potential therapy across the age spectrum of patients impacted by the host of pathophysiological complications of this devastating disease.
Hb oxidizes the heme iron from ferrous Hb to ferric Hb (metHb).
MetHb is unstable and releases hemin into the vascular space and it is hemin release that initiates the pathophysiological cascade ultimately resulting in the vascular damage underpinning the widespread tissue and organ damage that is the hallmark of this devastating disease. [8] [9] [10] In normal individuals, the released hemin is rapidly bound to circulating hemopexin with high affinity (K d < 10 213 M) and carried to CD91
(LRP1) receptors on hepatocytes for endocytosis and degradation. [11] [12] [13] However, in SCD patients the continuous formation of metHb in plasma and release of hemin depletes plasma hemopexin levels, in a similar manner to hemoglobin depleting haptoglobin, resulting in free hemin bound to lower affinity RBC-derived microparticles, albumin and lipoproteins. [14] [15] [16] [17] Hemin is released continuously from these carriers to cell membranes of circulating immune cells, platelets and endothelial cells in the vessel wall. 14, 18 Hemin in the cell membrane is cytotoxic, promotes oxidative stress, and activates innate immune toll-like receptor 4 (TLR4) signaling initiating activation of monocytes and endothelium. 8, [19] [20] [21] [22] [23] The resulting inflammatory cascades include degranulation of endothelial Weibel-Palade bodies, enzymatically-derived oxidant production, NF-jB-driven inflammasome activation, pro-inflammatory cytokine production, and adhesion molecule expression. Hemin, cytokines, lipopolysaccharide (LPS), infections, and the microbiome can all promote pro-inflammatory responses leading to adhesion of sickle RBCs, leukocytes, and platelets to the endothelium and the formation of multicellular aggregates leading to vaso-occlusion. 8, [24] [25] [26] [27] [28] The subsequent re-opening of occluded vessels promotes ischemia-reperfusion pathophysiology, inflammatory pain, and tissue injury that amplify the innate immune inflammatory responses. [29] [30] [31] SCD manifests clinically through a variety of severe morbidities, including stroke, auto-splenectomy with risk of resultant overwhelming infection, pulmonary hypertension, acute chest syndrome, infarction of organs, priapism, leg ulcers, and renal injury. 32 According to the Centers for Disease Control (CDC), the median survival among adults in North
America is approximately 42 years although a higher median survival rate was reported in an adult-only study in patients with SCD in the United Kingdom. 33 In addition to the impact on survival, the ravages of this microvascular occlusive disease severely and progressively impact the quality of life from infancy through adulthood. 34 Although sickle cell trait has been shown to have evolved in equatorial Africa, individuals with sickle trait have migrated to most major geographic regions of the world. 35 It is estimated that SCD affects approximately 100 000 Americans, 36 as well as approximately 37 000 patients in the EU, 37 and millions of patients globally. The prevalence of the disease is increasing as infant survival rises worldwide. 35 The number of children born with SCD is expected to exceed 14 million worldwide in the next 40 years, with about 79% of these children being born in sub-Saharan Africa in 2010 where the mortality is highest under 5 years of age. 38 A substantial medical need exists to reduce VOCs, also termed sickle cell crises and the consequent morbidities and mortality.
Hydroxyurea remains the only therapeutic approved for the prevention of VOCs in SCD. Hydroxyurea reduces, but does not eliminate the incidence of VOC's or the morbidities and mortality of SCD. In response to the unmet medical need, there are new therapeutics in development that target a variety of mechanisms, each with its own unique potential risks and benefits. 39 This review is focused on carbon monoxide (CO), as this small molecule gasotransmitter can impart potent salutary medical benefits based upon specific mechanisms of action at nontoxic low doses. We discuss the promising data that have emerged showing the benefits of CO and the efforts underway to develop it as a potent therapeutic.
| OVERVIEW OF THE H EME OXYGENASE/ CARBON MONOXIDE PATHWA Y
The discovery of nitric oxide (NO) gas in 1987 revealed the novel concept that endogenous production of a gas as a signal transmitter can impart diverse and critical systemic physiologic effects across a wide spectrum of biological and pathological processes. Unlike NO which is highly reactive, CO is stable. CO binds to cellular heme moieties and modulates the activity of heme-containing enzymes including mitochondrial oxidases, guanylate cyclase, nitric oxide synthase, and NADPH oxidase. 40, 41 Ultimately, the target for CO will depend on the cell type and the expression of hemoproteins that are present in the cell. For example, guanylate cyclase is highly present in vascular smooth muscle cells, but very low in endothelial cells.
CO is generated endogenously when heme is degraded by the heme oxygenase (HO) enzymes. Most, if not all, endogenous CO is generated by HO degradation of heme. These enzymes generate CO in the cytosol. In recent years, interest in HO has grown beyond its role as a metabolic enzyme that degrades heme with research exploding across multiple scientific disciplines. HO is now classified as an antiinflammatory cytoprotective enzyme that generates bioactive CO that mimics many of the effects of HO and has been described as an antiinflammatory gasotransmitter. In addition, heme degradation by HO produces iron that is stored in ferritin and the bile pigment biliverdin that is metabolized to bilirubin by biliverdin reductase (Figure 1 ). 72 In the lung, CO-mediated protection in wild-type mice was abrogated in mice null for the gene encoding plasminogen activator inhibitor (Pai1 -/-) mice. These data established a fundamental link between CO, hemostasis and the prevention of IRI based on the ability of CO to derepress the fibrinolytic axis. CO has been shown to be effective both prophylactically and therapeutically even when started at the peak of pathology. In short, CO seems to befit the need of the tissue to restore normal function. This has been defined as
How could CO modulate SCD? Exogenous CO may potentially affect SCD through six distinct mechanisms of action (Table 1) . First, CO could affect HbS polymerization. CO can bind to HbS polymers and enhance their melting which minimizes their persistence in red cells within the circulation, and their ability to rapidly seed additional polymers during transit in hypoxic tissues. These polymers may contribute to abnormal rheological flow and ultimately vaso-occlusion. 73 However, the equilibrium solubility of HbS with CO is linearly proportional to the amount of bound CO. 74 Thus, very high concentrations of CO may be required to have a clinical benefit in SCD through this mecha-
nism. Yet, Sirs showed a reduction of sickle RBCs from 10.2% to 3.9%
with a COHb level of 4% in blood from a single patient, 75 and there have been reports on studies of CO effects on HbS polymerization, with one showing in vitro binding of CO to sickle polymers 73 and a second study utilizing a microfluidic device showing concentrations of CO as low as 0.1% preventing occlusion when perfused with blood from SCD individuals. 76 The melting of polymers may be a key event minimizing the persistence of these polymers in the circulation and as a consequence, limiting these acting as a seed for rapid polymerization in hypoxic tissue. 73 Further, given the high affinity of CO for Hb, it is a logical supposition that the impact of CO on polymerization could limit sickle-associated clinical effects, but the extent and duration of these effect in vivo have received little focus. Second, CO inhibits the Ca 21 -permeable cation conductance channel or P-sickle, thereby inhibiting sickle RBC dehydration. 77 It has been postulated that an increase in RBC hydration could decrease the rate of HbS polymer formation.
Third, CO may have anti-oxidative effects by inhibiting the oxidation of ferrous HbS to ferric HbS through its ligation to heme and thereby preventing heme release from ferric HbS. 78, 79 CO may also inhibit superoxide production by NADPH oxidase 2 (NOX2) through CO binding to heme groups on the gp91 ph 8 x subunit. 80 In addition, CO activates Nrf2-responsive anti-oxidant genes including enzymes involved in glutathione production and regeneration, NADPH production, and iron sequestration such as HO-1 and ferritin.
Fourth, CO has remarkable anti-inflammatory properties through the activation of Nrf2-responsive genes leading to HO-1 upregulation and NF-jB downregulation. 51 A wide spectrum of genes are modulated by CO including Nrf2, NF-jB, STAT3, CREBH and various MAP kinases. 51, 54, [56] [57] [58] [59] [60] [61] CO has been shown to modulate inflammation by increasing HIF1a and PPARɤ signaling, largely dependent on the ability of CO to generate reactive oxygen species, generated in large part by the mitochondria. [81] [82] [83] [84] Clues to the protective effect of CO are bioavailability that is involved in the observed benefits. 114, 115 Sixth, CO has anti-apoptotic activity by preventing mitochondrial depolarization, inhibiting cytochrome C release, suppressing p53 expression, and inhibiting caspase activation. [99] [100] [101] [102] Although the potential efficacy of CO in SCD may rely upon all of these mechanisms of action, the exact dosing regimen of CO and resulting COHb concentration to maximize efficacy and ensure safety, will depend on the interplay of these mechanisms in the clinical setting.
Currently available data indicates that given the relatively short half-life of CO, the prevention of polymerization through CO binding to HbS This work was extended further investigating the anti-inflammatory effects of CO in S 1 S-Antilles SCD mice. 116 In this study, treatment of SCD mice with 25 or 250 ppm of inhaled CO for 1 hour per day, 3 days per week for 8 to 10 weeks showed decreased vascular inflammation and end-organ pathology. Inhaled CO treatment significantly reduced total white blood cell, neutrophil and lymphocyte counts. Moreover, reduced staining for myeloid and lymphoid markers in the bone marrow was observed, and bone marrow exhibited a significant decrease in colony-forming units by granulocyte-macrophage colony-forming cell assays. Anti-inflammatory signaling pathways including phospho-Akt and phospho-p38 MAPK were also markedly increased in the livers of COtreated mice. Importantly, treated sickle mice had a significant reduction in liver parenchymal necrosis, reflecting the anti-inflammatory and antivaso-occlusive benefits of CO administration, and these effects were seen at a peak COHb level of 2% and at higher levels.
A follow-on study demonstrated that the protective effects of CO extended to two additional SCD transgenic mouse models using a PEGylated COHb molecule (MP4CO) for intravenous CO administration. the peripheral blood. 75 Beutler and colleagues extended this work, demonstrating that the administration of inhaled CO to two SCD adult patients increased Cr
51
-tagged RBC survival, suggesting that the rheologic properties of sickle cells were favorably influenced. 86 Importantly, although these two studies comprise a very limited number of patients, the Sirs study suggests the possibility of a relatively low minimum effective dose, which clearly will need to be studied in formal clinical trials. In addition, an epidemiologic study carried out in London showed a significantly lower hospital admission rate for VOC on days when higher ambient atmospheric levels of CO were recorded. 87 Importantly, this significantly lower hospital admission rate was not related to the other five atmospheric pollutants that were investigated.
| Safety studies of CO
The clinical safety of CO in SCD depends on the target dose and 
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Despite these supportive studies, the safety of CO at concentrations at or below COHb of 10% in SCD patients is based on limited data. Individuals with SCD may have underlying SCD-associated endorgan disease that may be negatively impacted by CO administration, which may result from less oxygen to tissues. It is also possible, but unlikely given the current data, that CO may actually increase HbS polymerization. Given the current limited information on the impact of CO in individuals with SCD, careful study in SCD patients is warranted.
| C O A ND N E U R O N AL I N JU R Y
CO has been shown to be of benefit in a number of animal models of organ ischemia, including brain, kidney, heart, liver, and gut ischemia. In SCD there are major concerns around cerebral ischemia, as cerebrovascular occlusive events (CVOE) in patients with SCD are common and are major clinical events that uniformly determine adverse outcomes. 95 These events can manifest across the age spectrum as overt strokes, but cerebral infarcts can also be silent, with the cumulative events over time resulting in chronic cerebral ischemia, cognitive impairment, and poor quality of life. 96, 119 Silent cerebral infarcts (SCI) documented by radiologic changes have been reported in 10% to 30% of patients with SCD 119 and a prevalence of SCI of 53% has been documented in adults with SCD. 120 The prevalence of clinical stroke in SCD is reported to be as high as 24% and a crippling CVOE can occur as early as two years of age, with the highest incidence being within the first decade of life. 95, 121 The incidence of stroke has been demonstrated to be 10% 4.1 | The potential for HO-1 and CO to limit cerebro-vascular occlusive episodes in sickle cell disease
Neuroprotective strategies that aim to reduce neuronal damage are an important approach to improving CVOE outcomes in SCD. These strategies have been explored and primarily carried out in nonsickle cell animal models including stroke, autoimmune inflammation, and traumatic 
| HO and CO in cerebral ischemia
Data from six studies from four independent laboratories 69, [125] [126] [127] [128] [129] implicate HO-1 and CO in limiting non-SCD cerebral ischemia and suggest that targeting this pathway will offer a novel approach to the treatment of CVOE in SCD. Additional research provides support for these observations.
Panahian and colleagues first showed that HO-1 provides neuroprotection in cerebral ischemia. 126 129 The study demonstrated decreased infarct size after COHb administration (with approximately 5% peak COHb levels) 3 days after MCAO as well as increased blood flow to the infarct border zone. Importantly, these studies demonstrate that administration of CO, using various delivery strategies, has similar and significant neuroprotective effects after acute ischemic stroke.
| HO and CO in cerebral inflammation
Abundant data indicate that low CO levels modulate the immune response to limit detrimental autoimmune neuroinflammation. Following ischemic stroke there is a breakdown in the blood-brain barrier that allows cells of the systemic immune system to gain access to the ischemic brain. 128, 130, 131 Antigens that are normally sequestered from the immune system may thus be encountered in the brain as well as in peripheral lymphoid organs. Indeed, by 24 hours after the induction of experimental cerebral ischemia, lymphocytes are found within the central nervous system (CNS) and CNS antigens (for example proteolipid protein) are being presented to the immune system in cervical lymph nodes. 132 These observations suggest that an autoimmune response to brain antigens could develop after stroke. In fact, studies in the 1970s
showed that stroke survivors had more robust cellular immune responses towards myelin basic protein (MBP) and "brain antigens"
than patients with multiple sclerosis and acute inflammatory demyelinating polyneuropathy. [133] [134] [135] Additional data demonstrate lymphocyte responses to MBP and antibody responses to neurofilament and portions of the N-methyl-D-aspartate receptor among stroke survivors. [136] [137] [138] These immune responses have been largely considered an epiphenomenon of cerebral tissue injury.
In experimental and clinical studies, both animals and patients who develop TH1 immune responses in the brain, suffer worse stroke outcomes. 124, [139] [140] [141] It has also been shown that TH17 responses negatively impact stroke outcome. [142] [143] [144] [145] [146] [147] These data suggest that the postischemic immune responses affect outcome. It has been shown that induction of MBP-specific TREG responses prior to ischemia prevents TH1 responses to MBP and improves outcome. 140, 148, 149 Therapies that can be initiated in a delayed time frame after stroke onset, especially when tissue plasminogen activator is not indicated, including CVOE in SCD, are sorely needed and the modulation of the immune response is an intervention that has potential for improving outcome.
In addition to the potential neuroprotective properties of CO, there are abundant data suggesting that CO modulates immune responses and limits detrimental autoimmune inflammation. CO has multiple effects on the immune system, which in sum, are associated with decreases in inflammation and detrimental TH1 and TH17 responses. Importantly, as pertains to the systemic encounter of CNS antigens after stroke, CO inhibits the capacity of dendritic cells to present soluble antigens to T cells, 150 which may, in part, be related to a block in the up-regulation of TLR4. 148 CORMs increased expression of HO-1, reducing the secretion of IFN-g and IL-17 from T cells. 151 CO also blocks the production of IL-2 in naïve T cells, 152 thereby inhibiting T cell proliferation. These effects are well demonstrated in models of experimental allergic encephalomyelitis (EAE). In the EAE model, these effects were associated with a decrease in CD8 T cell accumulation in the CNS, a decrease in MHCII expression in the CNS, inhibition of TH cell proliferation and effector cell function, and a decrease in myelin-reactive T cell proliferation. 149 Of note, the effects of CO appear to be directed towards inhibition of TH1 and TH17 responses as opposed to up-regulation of TREG responses as the secretion of TREG cytokines was not affected. 151 Given the inhibitory effects of CO on the development of the TH1 and TH17 immune responses, and the fact that it can halt ongoing EAE, CO appears poised to be an effective immune modulator in postischemic settings including SCD-associated CVOE.
| HO and CO in brain injury
A number of studies in various in vitro and in vivo models of cerebral injury demonstrate that CO provides neuroprotection, providing support for the use of CO in the treatment of SCD-associated CVOE's.
Four studies focused on in vitro cellular injury models in neurons, astrocytes and microglia demonstrated that CO prevents apoptosis. [103] [104] [105] 153 Vieira and colleagues demonstrated that preconditioning with CO gas inhibits apoptosis in murine cerebellar granule cells treated with either glutamate or tert-butylhydroperoxide (t-BHP) to mimic excitotoxicity and oxidative stress, respectively. CO treatment induced de novo protein synthesis in these cells. This study also demonstrated that CO is a critical component of the anti-apoptotic role of HO-1, as it was found that exogenous CO administration could reverse the lack of HO-1 in an oxidative stress model. Queiroga et al., found that the anti-apoptotic properties of CO extended to astrocytes where it prevented apoptosis induced by either t-BHP or diamide, a thiol crosslinking agent. CO inhibited increases in mitochondrial membrane permeability, a key event in the intrinsic apoptotic pathway. 104 Almeida and colleagues confirmed these effects showing that CO stimulates oxidative phosphorylation and improves metabolism, in part by preventing caspase-3 activation, mitochondrial depolarization, and changes in plasma membrane permeability. 105 Additionally, Bani-Hani and colleagues showed that CO treatment using a CORM attenuated thrombin-induced activation of BV-2 microglia and reduced lactate dehydrogenase, a marker for cell breakdown. 153 Moreover, inhibition of HO-1 did not change the activity of CO, suggesting that CO is directly responsible for the observed neuroprotective effects. Finally, Yabluchansky et al utilized CORM-3 in a rat model of hemorrhagic stroke to demonstrate that CO reduces brain damage via a modification of the inflammatory response. 154 Three in vivo studies in models of cerebral injury have been described. [155] [156] [157] The first report demonstrated the cerebro-protective effects of CO, delivered using a CORM, in a seizure-induced neonatal vascular injury model in piglets. 155 In this study, CO pretreatment, in within neural stem cells. This study suggests that CO treatment prevents pericyte death and promotes neurogenesis. 157 Collectively, these data suggest that chronic administration of CO, in addition to preventing VOCs, could also mitigate the morbidities caused by specific organ ischemia, including the brain in SCD patients.
Despite the accumulating and abundant encouraging preclinical data that support the potential impact of HO and CO on improving SCD-CVOE outcomes, studies in human subjects with SCD need to proceed with caution given the host of SCD-associated organ morbidities. For example, cerebral blood flow reserve in SCD patients is often reduced and, given the possible reduction in cerebral oxygen reserve that may occur under raised CO-Hb levels, carefully constructed adequately controlled studies will be required in order to determine the risk/benefit ratio with CO in these patients. 
| M E T H O D S OF CO A D M I N I S T R A T I O N

| Inhaled CO
Although inhaled CO is the most obvious form of CO administration, this presents substantial challenges for further development, especially for chronic use that would be required for the prevention of VOCs. CO gas for inhalation is readily and commercially available and this route of administration has been used to generate the vast majority of preclinical and clinical data regarding CO and SCD. Inhaled CO, however, is difficult to accurately dose given the variability of patient ventilation, mask and cannula compliance, and pulmonary absorption associated with the variable capacity of the lung. Inhaled CO also has environmental safety concerns, as it requires the presence of large amounts of CO gas in cylinders. In addition, the chronic use of CO gas in an outpatient or home environment, as would be necessary for the use in the prevention of SCD VOCs, has significant logistical and compliance hurdles for patients, and potential exposure risks to others in close proximity. Despite the above challenges, the administration of inhaled CO is being utilized in a number of ongoing non-SCD targeted 159 and hybrid CO-RMs that are tethered to molecules that are known to induce HO-1 are also under evaluation. 162 These approaches as well as other, similarly innovative approaches are being explored in the development of CORMs, 154, 162 with particular focus on minimizing toxicity and permitting dosing at levels likely to permit the evaluation of efficacy. Given the potential clinical trial with Sanguinate in the treatment of VOCs is ongoing (NCT02411708). However, in the case of these Hb-based compounds, the announced intent of the companies as well as the documented toxicity of cell-free Hb suggest that these molecules, should they succeed in clinical development, would be limited to acute use for treatment of VOC rather than chronic use for the prevention of VOC. 163 As an added issue, when heme is released from the exogenously administered hemoglobin, substantial acute changes that could result in toxicity as reported with hemoglobin solutions may occur, 163, 164 and the potential for iron overload also exists if used for chronic treatment.
Regardless, as new small and large molecule CORMs with a spectrum of chemical properties, reactivity and toxicology are being developed, these may result in novel innovative agents for this highly challenging disease.
| Oral formulation of CO
The potential to orally administer CO in a liquid formulation has been pursued to avoid the barriers to development of inhaled CO and CORMs detailed above. 165, 166 CO is absorbed as well across gastrointestinal surfaces as across the pulmonary epithelium. 167 The development of a CO-containing liquid comprised of Generally Recognized as Safe (GRAS) excipients (HBI-002) was recently documented in abstract form and presented at research meetings. 165, 168, 169 The bioavailability of CO through oral administration of HBI-002 has been demonstrated in rodents, where an increase in COHb levels of up to 10% was achieved. Oral administration of CO avoids many of the issues associated with gas administration. As compared with inhaled CO, it allows more precise dosing and avoids environmental safety issues associated with compressed gas cylinders. In addition, it avoids the challenges associated with the reported CORMs, as no releasing molecule or reaction to release CO is required. Oral delivery of the liquid formulation provides a platform for feasibility and compliance given the preference for oral dosing by patients, especially for chronic administration and for the administration of a therapeutic outside of hospital settings.
| C O NC LU S I O N S
CO is physiologically generated during the metabolism of heme by the HO enzymes and is measurable in blood, typically correlating with the stress response. There is much therapeutic potential for using CO in higher than physiological doses, but at levels below known toxicity to treat SCD patients. This has been known for over fifty years. Substantial preclinical and clinical data with CO has been generated, providing In summary, CO has important anti-vaso-occlusive and immunomodulatory effects that, together, provide cells and tissues with powerful protective and pro-survival systems in the setting of SCD. In particular, considerable scientific data provide evidence for a beneficial impact of CO on cerebrovascular complications, suggesting that in SCD, CO could potentially limit these highly problematic neurologic outcomes.
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